Fatigue in Parkinson's Disease (P06.052)

Abstract

Objective: To assess the relationship between the Fatigue item on the MDS-UPDRS and other non-motor and motor symptoms of Parkinson9s disease (PD) as measured by the newly developed scale. Background Patients with PD report a high incidence of fatigue though it remains a poorly understood symptom. It is not clear whether fatigue relates to a single or multiple motor and non-motor symptoms of PD and what are the relative contributions of these associated symptoms to fatigue. Design/Methods: A retrospective analysis assessing the relationships between the Fatigue item (1.13) and different non-motor and motor components of MDS-UPDRS, was performed using the MDS-UPDRS validation database consisting of 877 subjects. Individual items exceeding a Kendall9s correlation of 0.20 (p Results: Fatigue showed stronger correlations with MDS-UPDRS items in Parts I and II (Non-motor Experiences of Daily Living and Motor Experiences of Daily Living), compared to items in Parts III and IV (Motor Examination and Motor Complications). Among the 24 motor and non-motor items that met criteria to enter the logistic regression, only six items significantly contributed, all derived from Parts I and II: Hobbies and Other activities contributed most to Fatigue (p Conclusions: Fatigue, as assessed by MDS-UPDRS, is a multi-factorial construct rather than being related to a single symptom. Mood, sleep and vegetative symptoms contribute significantly to ratings of fatigue, while motor symptoms do not. Whereas cause and effect relationships cannot be established, treatment of these non-motor associates to fatigue may offer options to abate fatigue. Disclosure: Dr. Homayoun has nothing to disclose. Dr. Stebbins has received personal compensation for activities with Impax Laboratories, Inc., Ceregene, Inc., Biovail Technologies, Ltd., Santhera Pharmaceuticals, and Ingenix Pharmaceutical Services. Dr. Stebbins has received research support from the National Institutes of Health, American Cancer Society, the Michael J. Fox Foundation, and Fragile-X Foundation. Dr. Tilley has received personal compensation for activities with Pfizer Inc, Human Genome and Novartis as a participant on a data and safety monitoring board and/or advisor. Dr. Goetz has received personal compensation for activities with Asubio Pharmaceuticals Inc., Campbell Alliance, CNS Therapeutics, Curry Rockerfeller Group, Health Advances, Impax Pharmaceuticals, Ingenix, Juvantia Pharma LTD as a consultant and participant on an advisory board. Dr. Goetz has received personal compensation in an editorial capacity for Movement Disorders and Oxford University Press. Dr. Goetz has received research support from Michael J. Fox Foundation, National Institute of Health and Parkinson9s Disease Foundation.